What Happened In After-Hours To Make Homology Medicines (FIXX) Stock Jump?

Related Topics


Homology Medicines Inc. (FIXX) shares were rising 14.56% to trade at $3.62 in after-hours at last check. Homology Medicines (FIXX) stock lost -3.07% to close Friday’s session at $3.16. The stock volume remained 0.25 million shares, which was lower than the average daily volume of 0.65 million shares within the past 50 days.

Homology Medicines shares have fallen by -67.95% over the last 12 months, and they have moved up by 4.64% in the past week. Over the past three months, the stock has lost -32.19%, while over the past six months, it has shed -58.53%. Further, the company has a current market of $180.59 million and its outstanding shares stood at 57.11 million. FIXX stock gained after hours following the close of a significant deal.

What deal did Homology Medicines close?

Homology Medicines (FIXX) is a clinical-stage hereditary drugs organization committed to changing the existences of patients experiencing interesting sicknesses by tending to the fundamental reason for the illness. HFIXX’s clinical projects incorporate HMI-102, investigational quality treatment for grown-ups with phenylketonuria (PKU); HMI-103, a quality altering contender for PKU; and HMI-203, investigational quality treatment for Hunter disorder. Extra projects of FIXX center around metachromatic leukodystrophy (MLD), paroxysmal nighttime hemoglobinuria (PNH), and different infections.

Homology Medicines (FIXX) on Friday declared the effective settling of the negotiation with Oxford Biomedica plc (LSE: OXB) to lay out an Adeno-Associated Virus (AAV) Manufacturing and Innovation Business.

  • The new organization, Oxford Biomedica Solutions LLC, consolidates FIXX’s specialized and producing tasks, group, and GMP office with OXB’s broad expertise in viral vector fabricating.
  • FIXX will keep up with admittance to the abilities that the Company worked on throughout recent years, as well as offer in potential advantages got from future advancements as a 20% proprietor and favored client of Oxford Biomedica Solutions.
  • As FIXX pushes its clinical projects and pipeline ahead, top-notch fabricating from an industry-driving group stays one of its most significant needs.
  • Stake in Oxford Biomedica Solutions furnishes FIXX with proceeded with admittance to specialists in its AAVHSC innovation stage with the additional advantages that our organization with worldwide viral vector producing pioneer OXB can bring.
  • Also, the $130 million in non-dilutive capital will be instrumental in propelling its own projects, while FIXX work with OXB to fabricate what we accept will be a profoundly fruitful business proposing to many organizations looking for excellent AAV items that patients merit.

What the arrangement will mean for FIXX?

This non-dilutive capital, along with a decrease in working costs connecting with assembling, will broaden FIXX’s money runway into the final part of 2024. Moreover, there is a chance for Homology Medicines (FIXX) to get further non-dilutive subsidizing whenever following the three-year commemoration of the arrangement.

Leave a Comment

Your email address will not be published.

Latest Posts